Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Zai Lab Ltd ( (HK:9688) ) has provided an announcement.
Zai Lab Limited has granted share options, restricted share units and performance share units to four employee participants under its 2024 Equity Incentive Plan, reinforcing its long-term incentive structure. The grants cover 374,220 American depositary shares in options and 121,620 ADS-equivalent restricted share units, with options vesting over four years, a ten-year validity period, and no attached performance targets or clawback mechanisms, reflecting the board’s view that these terms are market-competitive and aligned with the company’s retention and motivation objectives.
The most recent analyst rating on (HK:9688) stock is a Hold with a HK$15.50 price target. To see the full list of analyst forecasts on Zai Lab Ltd stock, see the HK:9688 Stock Forecast page.
More about Zai Lab Ltd
Zai Lab Limited is a biopharmaceutical company incorporated in the Cayman Islands and listed in both Hong Kong and on Nasdaq. The company focuses on developing and commercializing innovative medicines, using equity-based incentives to attract and retain key employees in a competitive global life sciences market.
YTD Price Performance: 13.41%
Average Trading Volume: 10,519,447
Technical Sentiment Signal: Sell
Current Market Cap: HK$17.43B
For a thorough assessment of 9688 stock, go to TipRanks’ Stock Analysis page.